Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Clinical trial NCT05301842 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05301842
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-28
- Primary completion
- 2026-02-23
- Enrollment
- 760
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.